Skip to main content
Premium Trial:

Request an Annual Quote

Nucleonics Files for Re-Examination of Benitec, CSIRO RNAi Patents in Australia

NEW YORK, Sept. 7 (GenomeWeb News) - US biotech firm Nucleonics said today that it has filed a request with the Commissioner of Patents in Australia to re-examine the validity of an RNAi-related patent previously issued to Benitec and the Commonwealth Scientific and Industrial Research Organization.

 

Nucleonics alleges that the specific patent in question, "Control of Gene Expression" (Australian patent number 743,316), should be invalid because the claims "lack novelty and do not involve and inventive step." The request cites 24 prior publications in support of the claim.

 

In March, Benitec filed a patent infringement suit in the USagainst Nucelonics and others for patent number 6,573,099, which covers DNA-directed RNAi. In August, Benitec settled with GenScript and Ambion, the two other companies that were named in the suit.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.